18A184

18A184 is a bone-targeted drug candidate developed by Atlanthera for the treatment of acute, severe, and chronic osteoarthritis. It utilizes Atlanthera's proprietary hydroxybisphosphonate (HBP) vectorization technology to deliver a meloxicam-derived active pharmaceutical ingredient specifically to bone and joint tissues. By targeting the drug directly to the site of inflammation, 18A184 aims to provide locally sustained anti-inflammatory effects while minimizing systemic adverse effects typically associated with non-steroidal anti-inflammatory drugs (NSAIDs). The drug is currently in the preclinical stage, having demonstrated proof-of-concept in rat models of moderate to severe osteoarthritis.